Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2022-07-15 Regulatory Filings
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Europeiska kommissionen godkänner Kinpeygo® för vuxna med primär IgA-nefropati
Regulatory Filings Classification · 100% confidence The document is a press release written in Swedish announcing that the European Commission has granted conditional marketing authorization for the drug Kinpeygo®. It details the significance of the approval, the commercialization partner (STADA), and summarizes key efficacy and safety data from the Phase 3 NefIgArd study. The text concludes with contact information for Investor Relations and a standard disclaimer regarding forward-looking statements, explicitly stating that the information is being made public under the EU Market Abuse Regulation. This structure—a formal announcement of a significant corporate/regulatory event (drug approval) accompanied by key data points and investor contact details—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since the core content is the announcement of a major regulatory milestone (approval) and not a comprehensive financial report (like 10-K or IR), and it is not merely announcing the publication of another report (RPA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if this approval was tied to a reporting period, but RNS is the most appropriate catch-all for significant, non-financial-statement regulatory news. Given the context of a major drug approval announcement, RNS is the most accurate fit as a general regulatory announcement.
2022-07-15 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Stiftelsen Industrifonden' in 'Calliditas Therapeutics AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights percentages. The structure, focusing on the resulting distribution of total holdings and the percentage of voting rights, is characteristic of a major shareholding notification. The document mentions the 'Reason for major shareholding notification' and reports the resulting percentage crossing a threshold (implied by the context of such filings, although the specific threshold crossing isn't explicitly stated as the trigger, the content is clearly a notification of holding size). This aligns perfectly with the definition for Major Shareholding Notification (MRQ).
2022-07-05 English
Antal aktier och röster i Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text is a short announcement in Swedish regarding the total number of shares and votes in Calliditas Therapeutics AB as of June 30, 2022, following the issuance of C-shares under an at-the-market program. This directly relates to changes in the company's capital structure (share count). The most fitting category is 'Share Issue/Capital Change' (SHA), as it details the resulting share count after an issuance. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend notice (DIV) or director dealing (DIRS). Given the specific nature of reporting the total share count after a capital event, SHA is the correct classification.
2022-06-30 Swedish
Number of shares and votes in Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the number of shares and votes due to the issuance of 5,908,018 class C-shares as part of an at-the-market program. This directly relates to a change in the company's capital structure via share issuance. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). The document is short and contains the core announcement, not just a notice about another report.
2022-06-30 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for Calliditas Therapeutics AB, specifically reporting the quantity of shares and the resulting percentage of voting rights after a transaction. The structure, focusing on 'Before the transaction' and 'After the transaction' percentages and share counts, is characteristic of insider trading or major shareholder notifications. Comparing this to the definitions, it most closely matches 'Major Shareholding Notification' (MRQ), which covers changes in significant share ownership levels crossing thresholds. It is not a Director's Dealing (DIRS) as it doesn't explicitly name a director, nor is it a general regulatory filing (RNS) as it fits the specific MRQ category.
2022-06-30 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Linc AB' in 'Calliditas Therapeutics AB'. It explicitly uses the term 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' share quantities and resulting voting rights percentages. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2022-06-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.